Loading...
•
Dec 31, 2022
Jazz Pharmaceuticals Q4 2022 Earnings Report
Jazz Pharmaceuticals' financial performance for Q4 2022 was announced, revealing strategic execution that drove record revenues in 2022.
Key Takeaways
Jazz Pharmaceuticals reported Q4 2022 total revenues of $972.123 million. The company's Xywav became the largest product by net sales. The company is positioned for total revenue and net income growth in 2023.
Xywav became the company's largest product by net sales in Q4 2022.
Epidiolex delivered compelling growth in Q4 2022 and is now launched and reimbursed in all five key European markets.
Received FDA approval of Rylaze supplemental Biologics Licensing Application (sBLA) for Monday/Wednesday/Friday (MWF) intramuscular (IM) dosing.
Positive top-line results from the pivotal trial of zanidatamab in BTC in December 2022 and the first overall survival data for zanidatamab from a Phase 2 trial in 1L HER2-expressing metastatic GEA in January 2023.
Jazz Pharmaceuticals
Jazz Pharmaceuticals
Jazz Pharmaceuticals Revenue by Segment
Revenue by Segment
Other Revenue
CapyFin.com Forward Guidance
Jazz Pharmaceuticals provided full year 2023 financial guidance with revenues between $3,675 to $3,875 million.
Positive Outlook
- Revenue between $3,675 - $3,875 million
- Neuroscience revenue between $2,675 - $2,825 million
- Oncology revenue between $950 - $1,050 million
- Gross margin at 93%
- Net income between $410 - $560 million
Challenges Ahead
- SG&A expenses between $1,197 - $1,277 million
- SG&A expenses as percentage of total revenues between 31% - 35%
- R&D expenses between $739 - $797 million
- R&D expenses as percentage of total revenues between 19% - 22%
- Effective tax rate between (32)% - (8)%